• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺导管原位癌(DCIS)的病理学与临床演变

Pathology and clinical evolution of ductal carcinoma in situ (DCIS) of the breast.

作者信息

Page D L, Lagios M D

机构信息

Department of Pathology, Vanderbilt University Medical Center, Nashville, TN 37232-2561.

出版信息

Cancer Lett. 1994 Oct 28;86(1):1-4. doi: 10.1016/0304-3835(94)90173-2.

DOI:10.1016/0304-3835(94)90173-2
PMID:7954344
Abstract

The therapy of ductal carcinoma in situ is controversial, but is being more and more decided by the pathologic evidence. What we know of the natural history of ductal carcinoma in situ is that the comedo and non-comedo examples seem quite different. As detailed in several reviews, the information from studies following patients after biopsy alone indicate a great difference between the small non-comedo examples of ductal carcinoma in situ and the larger comedo DCIS. The currently available evidence from cases which have been treated by planned surgical excision without radiation therapy would indicate that the non-comedo examples of DCIS may be adequately treated by this modality as indicated in several recent studies.

摘要

导管原位癌的治疗存在争议,但越来越多地由病理证据来决定。我们对导管原位癌自然史的了解是,粉刺型和非粉刺型病例似乎有很大不同。正如在几篇综述中详细阐述的那样,仅活检后对患者进行随访研究的信息表明,导管原位癌的小非粉刺型病例与较大的粉刺型导管原位癌之间存在很大差异。目前来自未经放射治疗而接受计划性手术切除病例的现有证据表明,正如最近几项研究所表明的,非粉刺型导管原位癌病例可能通过这种方式得到充分治疗。

相似文献

1
Pathology and clinical evolution of ductal carcinoma in situ (DCIS) of the breast.乳腺导管原位癌(DCIS)的病理学与临床演变
Cancer Lett. 1994 Oct 28;86(1):1-4. doi: 10.1016/0304-3835(94)90173-2.
2
Overview of the biology and management of ductal carcinoma in situ of the breast.乳腺导管原位癌的生物学特性与管理概述
Cancer. 1994 Jul 1;74(1 Suppl):350-61. doi: 10.1002/cncr.2820741321.
3
Ductal carcinoma in situ of the breast: impact of pathology on therapeutic decisions.乳腺导管原位癌:病理学对治疗决策的影响。
Am J Surg Pathol. 2003 Jun;27(6):828-31. doi: 10.1097/00000478-200306000-00015.
4
Prognostic classification of breast ductal carcinoma-in-situ.乳腺导管原位癌的预后分类
Lancet. 1995 May 6;345(8958):1154-7. doi: 10.1016/s0140-6736(95)90982-6.
5
Management of ductal carcinoma in situ.导管原位癌的管理
CA Cancer J Clin. 1995 Jul-Aug;45(4):244-53. doi: 10.3322/canjclin.45.4.244.
6
Controversies in the treatment of ductal carcinoma in situ.导管原位癌治疗中的争议
Surg Clin North Am. 1996 Apr;76(2):243-65. doi: 10.1016/s0039-6109(05)70437-0.
7
Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression.病理学观点。乳腺导管原位癌:关于一种新的简化组织学分类以及细胞增殖与c-erbB-2蛋白表达之间关联的提议。
Mod Pathol. 1994 Feb;7(2):257-62.
8
[Ductal carcinoma in situ of the breast].乳腺导管原位癌
Med Clin (Barc). 1993 Oct 30;101(14):548-56.
9
Management of lobular carcinoma in situ and ductal carcinoma in situ of the breast.乳腺小叶原位癌和导管原位癌的管理
Semin Oncol. 1996 Aug;23(4):446-52.
10
A proposal for the histopathological diagnosis of ductal carcinoma in situ of the breast.乳腺导管原位癌组织病理学诊断建议
Breast Cancer. 2000;7(4):321-5. doi: 10.1007/BF02966398.

引用本文的文献

1
Physical confinement induces malignant transformation in mammary epithelial cells.物理束缚会诱导乳腺上皮细胞发生恶性转化。
Biomaterials. 2019 Oct;217:119307. doi: 10.1016/j.biomaterials.2019.119307. Epub 2019 Jun 26.
2
COX-2 and PPARgamma expression are potential markers of recurrence risk in mammary duct carcinoma in-situ.环氧化酶-2(COX-2)和过氧化物酶体增殖物激活受体γ(PPARγ)的表达是乳腺导管原位癌复发风险的潜在标志物。
BMC Cancer. 2008 Jan 31;8:36. doi: 10.1186/1471-2407-8-36.